Multi-Centre Audit Of Myotonic Dystrophy In the UK: How Can We Improve Access to Care? (S11.001)

Abstract

<h3>Objective:</h3> To conduct a multi-centre audit on patient care in a cohort of DM1 patients attending tertiary neuromuscular centres in the UK, based on 2018 consensus-based care recommendations. To assess the impact of an implementation of a change in practice to improve the access to care. <h3>Background:</h3> Myotonic Dystrophy Type 1 (DM1) is the most common muscular dystrophy in adults. Structured multi-disciplinary care is essential for managing the multi-system involvement in DM1 to improve patient safety and to reduce mortality and morbidity. Access to care can be variable dependent on geographical area and proximity to specialised services and time available to the neurologist. <h3>Design/Methods:</h3> Standardised audit tool was developed by consensus to enhance collection of practically important aspects of DM1 care retrospectively. Four tertiary neuroscience centres geographically distant, in the UK, were selected. <h3>Results:</h3> Total of 375 patients (197 (53%) female, mean age 47 years (range 1–84)) with DM1 were analysed. 62% had adult-onset disease. Neurology teams reviewed 64% of patients at least once a year. Cardiology review was performed annually for 30% of DM1 patients; of patients with respiratory needs, only 12% were reviewed as per recommendations; Swallowing function was assessed in only 44% of those required; assessment of cognitive-impairment was conducted only in 12%. Next we implemented an allied health care professional (AHP) led DM1-clinic in one centre and we analysed the data from 35 DM1 patients over three months: Total of 35 patients were reviewed. Cardiology review rates increased to 68%(22/35) where 100% of DM1 patients had respiratory and swallowing assessments. <h3>Conclusions:</h3> This multi-centre UK audit identifies several significant areas of care that need optimising in DM1, even within dedicated neuromuscular clinics. This highlights an opportunity for a national initiative to establish minimum care standards. However innovative utilisation of available resources can at least improve some aspects of, timely access to care. <b>Disclosure:</b> Dr. Hewamadduma has received personal compensation in the range of $500-$4,999 for serving as a Consultant for UCB. Dr. Hewamadduma has received personal compensation in the range of $500-$4,999 for serving as a Consultant for ARENX. Dr. Hewamadduma has received personal compensation in the range of $500-$4,999 for serving as a Consultant for BIOGEN. Dr. Hewamadduma has received personal compensation in the range of $500-$4,999 for serving as a Consultant for ROCHE. The institution of Dr. Hewamadduma has received research support from Neurocare . The institution of Dr. Hewamadduma has received research support from Sheffield Charitable Trust. Dr. Hewamadduma has received personal compensation in the range of $5,000-$9,999 for serving as a Adult Expert with National Health Service England (NHSE). Mr. Lilleker has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Roche. Mr. Lilleker has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Sanofi. Mr. Kelly has nothing to disclose. Miss White has nothing to disclose. Mr. Whiter has nothing to disclose. Dr. Islam has nothing to disclose. Dr. Campbell has nothing to disclose. Dr. Mehboob has nothing to disclose. Dr. Vonberg has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Prova Health. Dr. Shanmugarajah has nothing to disclose. Dr. Grote has nothing to disclose. Dr. Viegas has nothing to disclose. Dr. Turner has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Dyne Therapeutics. Dr. Turner has received personal compensation in the range of $10,000-$49,999 for serving as an Expert Witness for Turner Partnership. The institution of Dr. Turner has received research support from MDUK.